{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T18:37:50Z","timestamp":1774377470671,"version":"3.50.1"},"reference-count":73,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Telo Genomics, Toronto, Ontario, Canada"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Classic Hodgkin\u2019s lymphoma (cHL) is a curable cancer with a disease-free survival rate of over 10 years. Over 80% of diagnosed patients respond favorably to first-line chemotherapy, but few biomarkers exist that can predict the 15\u201320% of patients who experience refractory or early relapsed disease. To date, the identification of patients who will not respond to first-line therapy based on disease staging and traditional clinical risk factor analysis is still not possible. Three-dimensional (3D) telomere analysis using the TeloView\u00ae software platform has been shown to be a reliable tool to quantify genomic instability and to inform on disease progression and patients\u2019 response to therapy in several cancers. It also demonstrated telomere dysfunction in cHL elucidating biological mechanisms related to disease progression. Here, we report 3D telomere analysis on a multicenter cohort of 156 cHL patients. We used the cohort data as a training data set and identified significant 3D telomere parameters suitable to predict individual patient outcomes at the point of diagnosis. Multivariate analysis using logistic regression procedures allowed for developing a predictive scoring model using four 3D telomere parameters as predictors, including the proportion of t-stumps (very short telomeres), which has been a prominent predictor for cHL patient outcome in a previously published study using TeloView\u00ae analysis. The percentage of t-stumps was by far the most prominent predictor to identify refractory\/relapsing (RR) cHL prior to initiation of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) therapy. The model characteristics include an AUC of 0.83 in ROC analysis and a sensitivity and specificity of 0.82 and 0.78 respectively.<\/jats:p>","DOI":"10.3390\/cancers16162816","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T08:54:08Z","timestamp":1723452848000},"page":"2816","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis by TeloView\u00ae Technology Predicts the Response of Hodgkin\u2019s Lymphoma to First-Line ABVD Therapy"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-7866","authenticated-orcid":false,"given":"Hans","family":"Knecht","sequence":"first","affiliation":[{"name":"Division of Hematology, Jewish General Hospital, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Jewish General Hospital, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6683-5348","authenticated-orcid":false,"given":"Marc N.","family":"Bienz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Jewish General Hospital, McGill University, Montr\u00e9al, QC H3A 0G4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Brousset","sequence":"additional","affiliation":[{"name":"Toulouse Cancer Center, Universit\u00e9 de Toulouse, 31000 Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4251-7203","authenticated-orcid":false,"given":"Lorenzo","family":"Memeo","sequence":"additional","affiliation":[{"name":"Pathology Unit, Department of Experimental Oncology, Mediterranean Institute of Oncology, 95029 Viagrande, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Shifrin","sequence":"additional","affiliation":[{"name":"Telo Genomics Corp., Toronto ON M5G 1L7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asieh","family":"Alikhah","sequence":"additional","affiliation":[{"name":"Telo Genomics Corp., Toronto ON M5G 1L7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif F.","family":"Louis","sequence":"additional","affiliation":[{"name":"Telo Genomics Corp., Toronto ON M5G 1L7, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5797-2201","authenticated-orcid":false,"given":"Sabine","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, MB R3T 2N, Canada"},{"name":"CancerCare Manitoba Research Institute, CancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.pathol.2019.09.005","article-title":"Hodgkin lymphoma: A review of pathological features and recent advances in pathogenesis","volume":"52","author":"Piris","year":"2020","journal-title":"Pathology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bienz, M., Ramdani, S., and Knecht, H. (2020). Molecular pathogenesis of Hodgkin lymphoma: Past, present, future. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186623"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_5","first-page":"497","article-title":"Standard therapy of advanced Hodgkin lymphoma","volume":"2009","author":"Kuruvilla","year":"2009","journal-title":"ASH Educ. Program Book"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score \u2265 3, high-risk Hodgkin lymphoma: First results of the phase III EORTC 20012 Intergroup Trial","volume":"34","author":"Carde","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_10","first-page":"316","article-title":"Response-adapted frontline therapy for Hodgkin lymphoma: Are we there yet?","volume":"2016","author":"Johnson","year":"2016","journal-title":"Hematol. 2014 Am. Soc. Hematol. Educ. Program Book"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_12","first-page":"1236","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): An interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","article-title":"Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study","volume":"107","author":"Evens","year":"2022","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1200\/JCO.18.00122","article-title":"Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III and IV Hodgkin lymphoma","volume":"36","author":"Huntington","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Raymakers, A., Costa, S., Cameron, D., and Regier, D.A. (2020). Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin\u2019s lymphoma: A probabilistic analysis. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07374-3"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/clinchem\/41.5.644","article-title":"Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation","volume":"41","author":"Coleman","year":"1995","journal-title":"Clin. Chem."},{"key":"ref_21","first-page":"3974","article-title":"Centrosome defects and genetic instability in malignant tumors","volume":"58","author":"Pihan","year":"1998","journal-title":"Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0092-8674(01)00492-5","article-title":"Switching and signaling at the telomere","volume":"106","author":"Blackburn","year":"2001","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1126\/science.297.5581.565","article-title":"Connecting chromosomes, crisis, and cancer","volume":"297","author":"Maser","year":"2002","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"De Lange, T. (2005). Telomere-Related Genome Instability in Cancer, Cold Spring Harbor Laboratory Press.","DOI":"10.1101\/sqb.2005.70.032"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.molcel.2007.10.005","article-title":"Human cancer cells harbor T-stumps, a distinct class of extremely short telomeres","volume":"28","author":"Xu","year":"2007","journal-title":"Mol. Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/jcb.22501","article-title":"Initiation of telomere-mediated chromosomal rearrangements in cancer","volume":"109","author":"Mai","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_27","first-page":"2101","article-title":"LMP1 mediates multinuclearity through downregulation of shelterin proteins and formation of telomeric aggregates","volume":"125","author":"Lajoie","year":"2015","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/leu.2008.314","article-title":"The 3D nuclear organization of telomeres marks the transition from Hodgkin to Reed\u2013Sternberg cells","volume":"23","author":"Knecht","year":"2009","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.3324\/haematol.2010.030171","article-title":"Dynamic chromosomal rearrangements in Hodgkin\u2019s lymphoma are due to ongoing three-dimensional nuclear remodeling and breakage-bridge-fusion cycles","volume":"95","author":"Guffei","year":"2010","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/annonc\/13.S1.19","article-title":"Genetic instability in Hodgkin\u2019s lymphoma","volume":"13","author":"Re","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1593\/tlo.12142","article-title":"Three-dimensional telomere signatures of Hodgkin-and Reed-Sternberg cells at diagnosis identify patients with poor response to conventional chemotherapy","volume":"5","author":"Knecht","year":"2012","journal-title":"Transl. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/cancers5020714","article-title":"Genomic instability: The driving force behind refractory\/relapsing Hodgkin\u2019s lymphoma","volume":"5","author":"Knecht","year":"2013","journal-title":"Cancers"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cuceu, C., Hempel, W.M., Sabatier, L., Bosq, J., Carde, P., and M\u2019kacher, R. (2018). Chromosomal instability in Hodgkin lymphoma: An in-depth review and perspectives. Cancers, 10.","DOI":"10.3390\/cancers10040091"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1593\/neo.91752","article-title":"Three-dimensional nuclear telomere architecture is associated with differential time to progression and overall survival in glioblastoma patients","volume":"12","author":"Gadji","year":"2010","journal-title":"Neoplasia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/B978-0-12-387688-1.00004-1","article-title":"Nuclear remodeling as a mechanism for genomic instability in cancer","volume":"112","author":"Gadji","year":"2011","journal-title":"Adv. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1158\/1078-0432.CCR-12-0087","article-title":"Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups","volume":"18","author":"Gadji","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"749-IN36","DOI":"10.1593\/tlo.13613","article-title":"Three-dimensional nuclear telomere organization in multiple myeloma","volume":"6","author":"Klewes","year":"2013","journal-title":"Transl. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Rangel-Pozzo, A., Yu, P.L.I., LaL, S., Asbaghi, Y., Sisdelli, L., Tammur, P., Tamm, A., Punab, M., Klewes, L., and Louis, S. (2021). Telomere architecture correlates with aggressiveness in multiple myeloma. Cancers, 13.","DOI":"10.3390\/cancers13081969"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jid.2020.09.032","article-title":"Three-Dimensional Telomeric Fingerprint of Mycosis Fungoides and\/or S\u00e9zary Syndrome: A Pilot Study","volume":"141","author":"Bienz","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1089\/thy.2013.0118","article-title":"Three-dimensional telomere dynamics in follicular thyroid cancer","volume":"24","author":"Wark","year":"2014","journal-title":"Thyroid"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1002\/jcp.27321","article-title":"Characterizing the three-dimensional organization of telomeres in papillary thyroid carcinoma cells","volume":"234","author":"Caria","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Drachenberg, D., Awe, J.A., Rangel Pozzo, A., Saranchuk, J., and Mai, S. (2019). Advancing risk assessment of intermediate risk prostate cancer patients. Cancers, 11.","DOI":"10.3390\/cancers11060855"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Rangel-Pozzo, A., Sisdelli, L., Cordioli, M.I.V., Vaisman, F., Caria, P., Mai, S., and Cerutti, J.M. (2020). Genetic landscape of papillary thyroid carcinoma and nuclear architecture: An overview comparing pediatric and adult populations. Cancers, 12.","DOI":"10.3390\/cancers12113146"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/labinvest.2010.2","article-title":"3D Telomere FISH defines LMP1-expressing Reed\u2013Sternberg cells as end-stage cells with telomere-poor \u2018ghost\u2019 nuclei and very short telomeres","volume":"90","author":"Knecht","year":"2010","journal-title":"Lab. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/labinvest.2017.33","article-title":"Disruption of direct 3D telomere\u2013TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed\u2013Sternberg cells","volume":"97","author":"Knecht","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Contu, F., Rangel-Pozzo, A., Trokajlo, P., Wark, L., Klewes, L., Johnson, N.A., Petrogiannis-Haliotis, T., Gartner, J.G., Garini, Y., and Vanni, R. (2018). Distinct 3D structural patterns of lamin A\/C expression in Hodgkin and Reed-Sternberg cells. Cancers, 10.","DOI":"10.3390\/cancers10090286"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2818.2001.00949.x","article-title":"Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy","volume":"204","author":"Schaefer","year":"2001","journal-title":"J. Microsc."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chuang, T.C.Y., Moshir, S., Garini, Y., Chuang, A.Y.-C., Young, I.T., Vermolen, B., Doel, R.v.D., Mougey, V., Perrin, M., and Braun, M. (2004). The three-dimensional organization of telomeres in the nucleus of mammalian cells. BMC Biol., 2.","DOI":"10.1186\/1741-7007-2-12"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cyto.a.20159","article-title":"Characterizing the three-dimensional organization of telomeres","volume":"67","author":"Vermolen","year":"2005","journal-title":"Cytom. Part A J. Int. Soc. Anal. Cytol."},{"key":"ref_51","first-page":"267","article-title":"Telomere length measurements using digital fluorescence microscopy","volume":"36","author":"Poon","year":"1999","journal-title":"Cytom. J. Int. Soc. Anal. Cytol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/jcb.20760","article-title":"The significance of telomeric aggregates in the interphase nuclei of tumor cells","volume":"97","author":"Mai","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/cyto.a.20395","article-title":"Alterations of centromere positions in nuclei of immortalized and malignant mouse lymphocytes","volume":"71","author":"Sarkar","year":"2007","journal-title":"Cytom. Part A J. Int. Soc. Anal. Cytol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Bax, B.E. (2022). Biomarkers in Rare Diseases 2.0. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23094582"},{"key":"ref_55","first-page":"275","article-title":"Burkitt\u2019s lymphoma. Distinction of subgroups by morphometric analysis of the characteristics of 55 cell lines","volume":"7","author":"Felman","year":"1985","journal-title":"Anal. Quant. Cytol. Histol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.5795","article-title":"Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia","volume":"256","author":"Chen","year":"2022","journal-title":"J. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0014-4827(61)90192-6","article-title":"The serial cultivation of human diploid cell strains","volume":"25","author":"Hayflick","year":"1961","journal-title":"Exp. Cell Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1126\/science.279.5349.349","article-title":"Extension of life-span by introduction of telomerase into normal human cells","volume":"279","author":"Bodnar","year":"1998","journal-title":"Science"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.molcel.2014.02.030","article-title":"Elucidation of the DNA end-replication problem in Saccharomyces cerevisiae","volume":"53","author":"Soudet","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1126\/science.aab3389","article-title":"Human telomere biology: A contributory and interactive factor in aging, disease risks, and protection","volume":"350","author":"Blackburn","year":"2015","journal-title":"Science"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13148-024-01680-4","article-title":"Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length","volume":"16","author":"Carlund","year":"2024","journal-title":"Clin. Epigenetics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e1001","DOI":"10.1002\/ctm2.1001","article-title":"Comprehensive molecular analysis of immortalization hallmarks in thyroid cancer reveals new prognostic markers","volume":"12","author":"Moya","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","article-title":"International Prognostic Score in advanced-stage Hodgkin\u2019s lymphoma: Altered utility in the modern era","volume":"30","author":"Moccia","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2217\/fon-2022-0963","article-title":"Unfavorable early-stage Hodgkin lymphoma: Assessment of patient characteristics in a real-world setting","volume":"19","author":"Gautam","year":"2023","journal-title":"Future Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3324\/haematol.2016.141846","article-title":"Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: Prognostic significance of measurements in the coronal and transverse planes","volume":"101","author":"Kumar","year":"2016","journal-title":"Haematologica"},{"key":"ref_67","unstructured":"Mohite, A., Rangarajan, V., Goda, J., Chugh, S., Agrawal, A., and Sengar, M. (2023). Metabolic tumor parameters complement clinicopathological factors in prognosticating advanced stage Hodgkin Lymphoma. Asia Ocean. J. Nucl. Med. Biol., 11."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"72219","DOI":"10.18632\/oncotarget.12663","article-title":"Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7150\/jca.13593","article-title":"Kinetics of circulating plasma cell-free dna in paediatric classical Hodgkin lymphoma","volume":"7","author":"Primerano","year":"2016","journal-title":"J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00277-022-04949-x","article-title":"Circulating tumor DNA in Hodgkin lymphoma","volume":"101","author":"Maco","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1038\/s41375-022-01717-8","article-title":"Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP","volume":"36","author":"Driessen","year":"2022","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management","volume":"97","author":"Ansell","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"102","DOI":"10.37349\/etat.2023.00125","article-title":"Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer","volume":"4","author":"Caputo","year":"2023","journal-title":"Explor. Target. Anti-Tumor Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/16\/2816\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:34:33Z","timestamp":1760110473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/16\/2816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":73,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["cancers16162816"],"URL":"https:\/\/doi.org\/10.3390\/cancers16162816","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]}}}